# Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

> **NCT00095693** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Anaplastic Thyroid Cancer
- Insular Thyroid Cancer
- Recurrent Thyroid Cancer
- Stage III Follicular Thyroid Cancer
- Stage III Papillary Thyroid Cancer
- Stage IV Follicular Thyroid Cancer
- Stage IV Papillary Thyroid Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **RADIATION:** fludeoxyglucose F 18
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging

## Key facts

- **NCT ID:** NCT00095693
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2005-08
- **Final completion:** 2011-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095693, "Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00095693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*